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Background: Non-alcoholic fatty liver disease (NAFLD) is a continuum of diseases that include simple steatosis and
non-alcoholic steatohepatitis (NASH) ultimately leading to cirrhosis, hepatocellular carcinoma and end stage liver
failure. Currently there is no approved treatment for NASH. It is known that bile acids not only have physiological
roles in lipid digestion but also have strong hormonal properties. We have synthesized a novel
chenodeoxycholyl-arginine ethyl ester conjugate (CDCArg) for the treatment of NAFLD.
Methods: Chemical synthesis of CDCArg was performed. Experiments for prevention and treatment of NAFLD were
carried out on C57BL/6 J male mice that were treated with high fat diet (HFD, 60% calories from fat). CDCArg or
cholic acid bile acids were admixture into the diets. Food consumption, weight gain, liver histology, intraperitoneal
glucose tolerance test, biochemical analysis and blood parameters were assessed at the end of the experiment after
5 weeks of diet (prevention study) or after 14 weeks of diet (treatment study). In the treatment study CDCArg was
admixture into the diet at weeks 10–14.
Results: In comparison to HFD treated mice, mice treated with HFD supplemented with CDCArg, showed reduced
liver steatosis, reduced body weight and decreased testicular fat and liver tissue mass. Blood glucose, cholesterol,
insulin and leptin levels were also lower in this group. No evidence of toxicity of CDCArg was recorded. In fact, liver
injury, as evaluated using plasma hepatic enzyme levels, was low in mice treated with HFD and CDCArg when
compared to mice treated with HFD and cholic acid.
Conclusion: CDCArg supplementation protected the liver against HFD-induced NAFLD without any toxic effects.
These results indicate that basic amino acids e.g., L-arginine and bile acids conjugates may be a potential therapy
for NAFLD.
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Non-alcoholic fatty liver disease (NAFLD) is a continuum
of diseases that include simple steatosis and non-alcoholic
steatohepatitis (NASH) ultimately leading to cirrhosis, he-
patocellular carcinoma (HCC) and end stage liver failure
which develop in the absence of excessive alcohol intake
[1-3]. NAFLD affects 30% of the general population and
70-80% of diabetic and obese patients [4-6]. Risk factors of
the disease include low physical activity, dietary factors,
gut microbiota genetic factors, oxidative stress and sleep
apnea [7], fructose enriched beverages [8] etc.* Correspondence: oren.tirosh@mail.huji.ac.il
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unless otherwise stated.Simple steatosis is considered to have a benign hepatic
pathological prognosis. In contrast, NASH is pathologic-
ally characterized by the presence of steatosis, inflamma-
tion and liver fibrosis and is related to increased mortality.
NASH is associated with liver related complications, and
it is a leading cause of liver transplantation [9].
Currently there is no approved treatment for NASH. It
has been known that bile acids have broad and powerful
hormonal properties as gene regulators as well as estab-
lished physiologic roles in digestion of cholesterol and
other lipids. These molecules participate in food digestion
as well as in energy homeostasis owing to their physical
properties in the enterohepatic circulation. Bile acids may
also act as hormones and therefore can influence tran-
scription and activate several signaling pathways [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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receptor (FXR) and G protein-coupled bile acid receptor
(TGR5). Functional studies have demonstrated that
both FXR and TGR5 play important roles in regulating
lipid and carbohydrate metabolism and inflammatory
responses. Importantly, activation of FXR or TGR5
lowers hepatic triglyceride levels and inhibits inflamma-
tion. These properties of FXR or TGR5 have indicated
that these two bile acid receptors are possible targets for
treatment of NAFLD [11].
Despite of the potential protective effect of bile acids
against NAFLD due to their signaling role, it is im-
portant to note that in animal models of NASH, bile
acids act to promote and to exacerbate liver disease.
For example, atherogenic diet that contains 0.5 percent
of cholic acid (CA) induces oxidative stress and steato-
hepatitis with hepatocytes ballooning accompanied by
insulin resistance, and down-regulates antioxidant
genes. Thereby, bile acids further aggravate steatohepa-
titis [12].
Previously it has been suggested that bile acids aggra-
vate the disease of NAFLD also in humans. Increased bile
acids levels, Deoxycholic, Chenodeoxycholic, and CA
were elevated in liver tissue of steatohepatitis patients
[13]. Another study analysed liver biopsies and serum
samples of 113 morbidly obese patients undergoing bar-
iatric surgery, healthy individuals, and moderately obese
NAFLD patients. In this study serum bile acids levels
were increased in NASH versus simple steatosis and the
NAFLD activity score (NAS) correlated with bile acid
levels. In addition, the bile acids transporter high-affinity
Na+ /taurocholate cotransporter polypeptide (NTCP)Figure 1 Chemical stucture of Chenodeoxycholyl–arginine-ethyl ester
Chenodeoxycholic acid (78.5 gm, 0.2 mol) was dissolved in DMF (250 mL)
chloroformate (20.16 mL) was slowly added to the mixture at 0°C. The mix
mixture of arginine ethyl ester dihydrochloride (60.28 gm, 0.22 mol) and tri
to a dropping funnel and slowly added to the mixture of mixed anhydride
(step 1). The mixture was stirred at room temperature overnight. The mixtu
collected by separating from water (77 gm). The water from step 5 was co
concentration was loaded above a silica bed (300 gm) and eluted with me
earlier fractions with 100% methylene chloride were discarded since they m
The later fractions were concentrated and provided a gummy residue (45 g
dissolved in methanol and combined. It was then purified on the Teledyne
chloride. The purification was carried out on Combi-Flash using the ELSD d
collected and concentrated on rotary evaporator to give compound 1 (50.8and the bile acids synthesizing enzyme cholesterol 7
alpha-hydroxylase (CYP7A1) were significantly up-
regulated in obese patients. Up-regulation of NTCP and
CYP7A1 indicate failure to activate small heterodimer
partner (SHP) upon FXR stimulation by increased bile
acids concentrations. Therefore, bile acids synthesis and
serum bile acids levels correlate with disease severity in
NAFLD [14].
In 1975 Yosef and Fisher [15] reported the presence of
L-arginocholate in isolated perfused rat liver. The struc-
ture was confirmed by mass spectrometry analysis.
Regular bile acids, as was analyzed in gallbladder, com-
mon ducts and duodenum are conjugated to glycine and
taurine. The role of the lesser known basic amino acid
bile acid conjugates is intriguing. One possibility is that
these bile acids may serve as antagonists to the effect of
the regular bile acids. The aim of this study was to
develop a novel bile acid molecule that can be used to
treat NAFLD and NASH. For that purpose an L-
Arginine ethyl ester and chenodeoxycholic acid conju-
gate (CDCArg) was generated and tested in nutritional
models of NASH.Results
Prevention study
Administration of CDCArg induces food consumption and
reduced body weight
Mice were fed the following diets for five weeks: low fat
diet (LFD, control), high fat diet (HFD), and HFD with
CA, CDCArg (Figure 1) or L-arginine Although diets
were given ab-libitum, food consumption of the HFD +CDCArg and diagram of synthesis. The synthetic pathway:
and tributylamine (95.3 mL) in 1000 ml round bottom flask. Ethyl
ture was stirred at 0°C for 30 min. In 500 ml round bottom flask, a
butylamine (95.3 mL) in DMF (200 mL) was prepared. It was transferred
prepared from chenodeoxycholic acid and ethyl chloroformate at 0°C
re was poured on ice and the gummy residue separated out was
ncentrated in a rotary evaporator.The residue obtained after
thylene chloride followed by methanol –methylene chloride (1:4). The
ostly contained impurities and solvents (i.e. DMF and tri-buylamine).
m). The crude product from step 7 (77 gm) and step 11 (45 gm) was
Isco 330 gm silica gel column using 10-15% methanol –methylene
etector. Three separate runs were performed. The pure fraction were
gm). Reaction was repeated following the above procedure.
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treatments, including the HFD group (Figure 2A).
However, surprisingly, CDCArg significantly inhib-
ited weight gain in HFD + CDCArg group compared
with HFD treatment. In fact, HFD + CDCArg-treated
mice had the lowest body weight compared to all the
other groups with the exception of the LFD control
group (Figure 2B). Interestingly, the combination of
a different primary bile acid, CA, together with the
HFD resulted in similar effects of increased appetite
and decreased body weight as of CDCArg. Moreover,
adipose tissue mass (testicular fat) was also signifi-
cantly lower in HFD + CDCArg group compared with
HFD group (Figure 2C).Effect of the compound CDCArg on blood glucose,
adipose tissue weight and plasma insulin & leptin levels
Blood glucose levels were significantly lower in HFD +
CDCArg group compared with HFD treated group
(Figure 3A). Similarly, plasma insulin and leptin levels
were also significantly lower in HFD +CDCArg group
compared with the HFD group (Figure 3B,C). Consistent
with the above mentioned results, in these experiments
the addition of CA or large dose of free L-arginine
(around 3 g/kg bw) to the HFD also had positive effects
much similar to CDCArg.Figure 2 Effect of CDCArg on body weight, food intake and adipose t
groups: Control - low fat diet (LFD), high fat diet (HFD), CDCArg (0.5% w/w
1.25% in the drinking water, n = 8-9 in each group. (A) Daily consumption
measured throughout the experiment at the beginning of each week. (C)
analysis of repeated measurements of weight. Different groups that are sta
letters.Role of CDCArg in preventing liver damage
Hepatic enzyme levels in plasma were measured as an indi-
cation of liver damage. Serum glutamic-pyruvic transamin-
ase (SGPT) and serum glutamic oxaloacetic transaminase
(SGOT) levels were significantly higher in HFD+CA group
compared with all other groups (Figure 4A,B). Con-
versely, plasma alkaline phosphatase levels were not sig-
nificantly elevated (Figure 4C). These results indicate
that CA is primarily toxic to hepatocytes and to a con-
siderably lesser extent to cholingiocytes in the liver,
while CDCArg is not toxic to either cell type.
Hepatomegaly (enlarged livers) can results from sev-
eral causes including infection/inflammation and meta-
bolic disorders. Indeed, accumulation of lipids in the
liver can lead to increased liver weight. Liver weight was
substantially lower in HFD + CDCArg group compared
with the HFD and HFD + CA groups (Figure 4D). Histo-
logical evaluation by H&E staining showed elevated stea-
tosis (score of 3) in the HFD group, while in the HFD +
CDCArg group liver steatosis did not differ from that of
the control group (Figure 4E).
In comparison to the histological features of CA +
HFD treated mice, CDCArg + HFD treated mice showed
major differences regarding parameters related to liver
damage and hepatocyte injury. In HFD + CA treated
mice massive hepatocytes necrosis was observed which
correlated with elevated levels of blood liver enzymesissue weight. Mice were fed (Ad libitum) for 5 weeks. Treatment
) added to the HFD, HFD + cholic acid (CA, 0.5% w/w) and HFD + L-arg
of food at weeks 2, 3, 4 and 5. (B) Animals weight: Animals weight was
Testicular adipose tissue weight. Statistics were performed using
tistically different with probability of P < 0.05 are indicated by different
Figure 3 Effect of the compound CDCArg on blood glucose levels, serum insulin and leptin levels. Mice were fed (ad libitum) for 5 weeks
with LFD, HFD, HFD + CA, HFD + CDCArg and HFD + Arg. (A) Blood glucose levels, (B) Serum insulin or (C) leptin levels. Values are expressed as
mean ± SEM (n = 8-9 animals per group). Means without a common letter are statistically different. Means with *are statistically higher compared
to all other groups, p < 0.05.
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in HFD + CDCArg treated mice, no evidence of liver in-
jury was found and their phenotype did not differ from
the control group. To exclude the possibility that these
results may be the outcome of general toxicity of the
compounds, additional parameters (plasma creatinine,
sodium, potassium and chloride levels) were evaluated.
No significant differences among groups were observed
(Additional file 1: Figure S1).
Effect of the compound CDCArg on plasma lipid profiles
In HFD treated animals TG levels were evaluated. CDCArg
had a tendency to ameliorate TG levels (Figure 5A). In
addition, while plasma cholesterol levels were significantly
elevated in HFD group no increase was evident in HFD+
CDCArg and HFD+CA (Figure 5B).
Effect of the compound CDCArg on FXR and SHP
expression
Since plausibly CDCArg can protect the liver by activating
FXR nuclear receptor, the capacity of the compound to ac-
tivate this orphan receptor was evaluated. FXR gene expres-
sion was suppressed by HFD and was further suppressed
by the addition of CA (Figure 6A). Corresponding with the
decrease in FXR expression, HFD also downregulated SHP
mRNA levels, indicating limited capacity to activate FXR
signaling pathways (Figure 6B). These results indicate that
the FXR expression is suppressed by the HFD and evenmore by the addition of CA to the diet. In contrast,
CDCArg did not further suppressed the expression of
FXR as compared to HFD alone.
Recently, the accumulation of cholesterol was sug-
gested to have pathological effects in the liver. Thus, in
order to evaluate whether CDCArg has an impact on
FXR activation in the presence of cholesterol, primary
rat hepatocytes were incubated with cholesterol for 24 h
with the addition of chenodeoxycholic acid (CDCA) or
CDCArg. Under these conditions, only CDCA was able
to activate FXR as was indicated by elevated mRNA
levels of SHP (Additional file 2: Figure S2).
Treatment study
In order to determine the effects of CDCArg following
the onset of liver steatosis, mice were treated for 10 weeks
with HFD (ad libitum) to induce hepatic fat accumulation.
Thereafter, the HFD-fed mice were divided into two
groups, with or without CDCArg 0.5% w/w. In this experi-
ment, mice were pair-fed (15.5 kcal/day per mouse) to
compensate the hyperphagic effect of CDCArg. The low
fat diet (LFD) control group consumed on average the
same amount of calories per day per mouse. The duration
of treatment with CDCArg was 4 weeks.
Effect of CDCArg on mice weight and metabolism
As expected, consumption of HFD for 10 week led to
an increase in total body weight. However, while body
Figure 4 Effect of CDCArg on hepatic enzyme levels in the serum, liver weight and liver histology. Mice were fed (ad libitum) for 5 weeks
with LFD, HFD, HFD + CA, HFD + CDCArg and HFD + Arg. (A-C) Serum SGPT, SGOT or Alkaline Phosphatase levels. (D) Liver weight.
(E) Representative liver histological sections stained with H&E: (magnification 400X). Arrows indicate hepatocytes steatosis and Arrow heads
indicate hepatocytes damage (necrosis or apoptosis). Values are expressed as mean ± SEM (n = 8-9 animals per group). Means with different
letters are statistically different. Means with *are statistically higher compare to all other groups, p < 0.05.
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HFD, the addition of CDCArg to HFD prevented continu-
ation of weight gain (Figure 7A). Adipose tissue weight
was also substantially lower in HFD +CDCArg group
(Figure 7B). To assess the impact of CDCArg on intestinal
fat absorption, fecal lipid contents were measured. As
shown in Figure 7C fat content in feces was significantly
higher in CDCArg treated group. Thus, CDCArg at
least in part, inhibits intestinal fat absorption. Accord-
ing to the Merck veterinary manual: malabsorption syn-
drome in small animals and low plasma albumin levelsFigure 5 Effect of CDCArg on serum lipids. Mice were fed (ad libitum) f
(A) Plasma triglycerides levels. (B) Plasma total cholesterol (total) levels. Memay indicate lower protein absorption. Plasma albumin
levels were significantly higher in HFD + CDCArg group
than in HFD group, indicating that protein absorp-
tion was not compromised by the supplementation of
CDCArg (Figure 7D).
The effect of CDCArg on insulin resistance was evalu-
ated using interperitoneal glucose tolerance test (IPGTT)
in mice. CDCArg supplemented mice exhibited a lower
average peak in blood glucose during IPGTT, and im-
proved glycemic response compared with HFD group
(Figure 8).or 5 weeks with LFD, HFD, HFD + CA, HFD + CDCArg and HFD + Arg.
ans with different letters are statistically different, p < 0.05.
Figure 6 FXR and SHP expression. Mice were fed (ad libitum) for
5 weeks with LFD, HFD, HFD + CA, HFD + CDCArg and HFD + Arg.
Gene expression of FXR and SHP were evaluated by RT-real time
PCR, (A) FXR mRNA expression. Means with different letters are
significantly different, LSD test P < 0.05. (B) SHP expression. Control
is different from all other groups, Dunnett's test test p < 0.05.
ribosomal 18S was used as the normalizing gene.
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SGPT and SGOT levels were significantly lower in
the HFD + CDCArg compared with the HFD group
(Figure 9A,B). Alkaline phosphatase levels in plasma were
not significantly altered (Figure 9C). Consistently, liver
weights were also significantly lower in HFD + CDCArg
group (Figure 9D). In agreement with these results,
histological evaluation revealed lesser liver micro and
macrovesicular steatosis in the HFD + CDCArg group
than in the HFD group. Lobular inflammation was also
observed in the control group but not in the HFD +
CDCArg group (Figure 9E). Analysis of gene expression
showed that CDCArg activates genes that are related to
energy expenditure, peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC1α) and per-
oxisome proliferator-activated receptor alpha (PPARα),
while CDCArg suppressed the key gene that regulates
denovo lipogenesis sterol regulatory element-binding
protein 1c (SREBP1c) (Additional file 3: Figure S3.). No
statistical difference in AMPK activation was observed
in any of the treatments. However, the ratio of pAMPK
to AMPK was tend to be higher in the HFD + CDCArg
treated group (Data not shown).Effect of CDCArg in high cholesterol diet treated rats
In rats fed a high cholesterol diet, CDCArg unlike CA,
did not potentiate the toxic effect of free cholesterol in
the liver (Additional file 4: Figure S4). CDCArg did not
aggravate the effect of cholesterol on liver mass or on
the levels of hepatic transaminases in the serum.Discussion
The capacity of bile acids to protect or aggravate fatty
liver disease is not clear. In terms of liver damage CA is
considered a food toxin. Feeding rodents with bile acids
has been used to study bile acid toxicity in vivo. The
ability of the bile acids to produce hepatotoxicity is con-
sidered to be: UDCA < CA < CDCA <DCA < LCA [16].
Feeding rats a high cholesterol diet in the absence of bile
acids resulted in relatively moderate liver damage com-
pared to feeding of cholesterol in the presence of CA. In
contrast to CA, CDCArg did not potentiate cholesterol
toxicity (Additional file 4: Figure S4).
We have used bile acids in combination with saturated
fatty acids from a plant source (palm stearin, containing
around 50 percent of saturated fatty acids) that is chol-
esterol free. To the best of our knowledge, we are the
first to report that CA administrated together with HFD
rich in saturated fat in the absence of cholesterol poten-
tiates liver damage. This was demonstrated by an eleva-
tion of liver enzymes in the blood. HFD, while contains
fat of plants origin, has only a small capacity to induce
liver damage. However, toxic bile acids may cause in-
flammation, apoptosis, and cell death [17]. Currently it
is not clear if the deleterious effect of CA to the liver
was synergistic or simply additive to the effect of the
fatty acid rich diet. However, in contrast to CA, CDCArg
did not generate toxic effects in the liver and did not in-
duce general toxicity. Electrolyte imbalance and kidney
damage were not observed during the in vivo treatments
indicating no acute toxicity of the diets. CDCArg ame-
liorated HFD-induced liver steatosis. Also blood liver en-
zymes levels were lower normalizing the long term
effect of feeding with HFD (treatment study). Hepato-
megaly was corrected by CDCArg. All these parameters
indicate that CDCArg may be used with efficacy and
safety for NAFLD and NASH treatment.
In the clinical setting both CDCA and urosodeoxy-
cholic acid (UDCA) have failed as an approved treat-
ment for NASH [18]. The results of a randomized
controlled trial of UDCA in NASH patients were disap-
pointing, and no measurable benefit could be attributed
to UDCA. Likewise, in a smaller, randomized, controlled
study carried out in Switzerland no benefit of UDCA
over placebo was found when looking at liver histology
in NASH patients. However, there was a beneficial effect
of UDCA on ALT levels in this trial.
Figure 7 Effect of CDCArg on mice weight, testicular adipose tissue weight, fecal fat and plasma serum albumin. Treatments: Mice were
fed with LFD for 14 weeks or with HFD for 10 weeks. At week 10 the HFD group was divided randomly into two equal groups that were pair fed.
One group received HFD, while the other group received HFD + CDCArg. (A) Mice weight as measured during the experiment at the beginning
of each week. *p < 0.05, lower weight compared to HFD. (B) Weight of adipose testicular tissue. (C) Feces fat percent (week 13): Total lipids were
extracted from feces using Folch’s method after collecting feces during this week. Mean with *is statistically higher than HFD group, p < 0.05. n =
6, t-test. (D) Serum albumin levels in treated mice. *p < 0.05. t-test.
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activator obeticholic acid, that is under clinical investiga-
tion, have demonstrated adverse side effects of elevated
LDL cholesterol [10].
Bile acids are used in an animal models of an athero-
genic diet supplementation to potentiate the effect of
cholesterol. It has been noted that the atherogenic diet
can lead to the development of NASH. Atherogenic diets
have been show to induce dyslipidemia, lipid peroxidation,Figure 8 Effect of CDCArg on insulin resistance as evaluated by
intra-peritoneal glucose tolerance test (IPGTT). IPGTT was
perform at week fourteen. Values are expressed as mean ± SEM
(n = 8-9 animals per group). Means with *are statistically higher, one
way ANOVA and Post Hoc dunnett test.stellate cell activation, precirrhotic steatohepatitis and
cellular ballooning. Atherogenic diets in contrast to
other animal models of NASH, such as the methionine
and choline deficiency diet, induce the necessary histo-
logical features similar to those found in human NASH.
It also generates a phenotype of insulin resistance. The
addition of a high-fat component to the atherogenic diet
exacerbated hepatic insulin resistance and further accel-
erated the pathology of steatohepatitis [12]. Therefore,
it is extremely important to develop bile acid based
therapy that is free of such deleterious effects.
Bile acid sequestrates have been used for many years
to treat hypercholesterolemia and dyslipidemia. On the
other hand, bile acid-activated nuclear and GPCR signal-
ing pathways may protect against inflammation in the
liver. In the current study, treatment with CDCArg im-
proved fasting glucose levels, insulin and leptin sensitiv-
ity and reduced testicular fat accumulation induced by
HFD in the mouse model.
Bile acids can enter the hepatocytes in several ways. The
entry of bile acids into hepatocytes at the sinusoidal sur-
face takes place by NTCP, Na+-dependent pathway that is
driven by the transmembrane Na+-gradient [19]. NTCP is
exclusively expressed in hepatocytes and localized at the
sinusoidal membrane. In addition there is a less efficient
system for uptake Na+-independent and involves several
members of the organic anion transporting polypeptide
Figure 9 Effect of CDCArg on serum hepatic enzyme levels, liver weight and liver histology. Treatments: Mice were fed with LFD for
14 weeks or with HFD for 10 weeks. At week 10 the HFD group was divided randomly into two equal groups that were pair fed. One group
received HFD, while the other group received HFD + CDCArg. (A-C) Average serum SGPT, SGOT or Alkaline Phosphatase levels. (D) Liver weight.
(E) Representative liver histologic sections stained with H&E (Magnification 200X).
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dependent bile salt transporter is expressed at high
levels in the terminal ileum, renal proximal tubules, and
biliary epithelium. CDCArg, due to its net positive
charge, most probably cannot or is not expected to be
absorbed efficiently back into the liver and therefore is
probably translocated into the colon dragging along fat
and preventing fat absorption. However, evaluation of
plasma albumin levels indicated that CDCArg did not
impair protein absorption in mice.
In the current study we investigated a primary bile
acid (chenodeoxycolic acid) that was conjugated to L-
arginine. The arginine guanidino group of its side chain
provides a constant net positive charge to the molecule
throughout the range of physiological pH range. The
pKa of guanidine is 12.5, indicating that this compound
will exist almost entirely as a cation in the in vivo envir-
onment. According to our results such a bile acid did
not potentiate cholesterol-induced liver damage and
protected against deleterious effects of HFD composed
of high amounts of saturated fat.
The effect of CDCArg in HFD-induced obesity in
mice was tested. Two main effects were noted, increased
consumption and decreased body weight gain. In generalbile acids may possess an anti-obesity properties by acti-
vation of the TGR5 receptor. TGR5 is a novel pharma-
cological target in the metabolic syndrome and related
disorders, such as diabetes, obesity, atherosclerosis, liver
diseases and cancer [20]. However, its clinical effect is
yet to be elucidated. Activation of TGR5 by bile acids re-
leases incretins and improves glycemic control in a ro-
dent nutritional model of HFD [21]. However, bile acids
do not appear to be key mediators of the early increase
in GLP-1 and PYY response in post-bariatric patients
[22]. Therefore, the role of bile acids in obesity treat-
ment is still unclear. Recently it has been shown that
dietary fats, by promoting changes in host bile acid com-
position, can markedly alter conditions of the gut micro-
bial environment due to sulfur containing bile acids,
resulting in perturbation of immune homeostasis. A diet
high in saturated fat promoted taurine conjugation of
hepatic bile acids and promoted induction of colitis [23].
CDCArg, due to its different chemical properties, may
offer a possible treatment for obesity as it directly affects
weight gain. Its specific effects on gut polypeptide secretion
and its anti-obesity mechanism still need to be clarified.
CDCArg + HFD in oppose to HFD decreased blood
leptin levels, which could indicate the amelioration of
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leptin resistance on disease progression and the meta-
bolic syndrome is complicated [24,25]. Whether or not
the effect of CDCArg is via leptin still needs to be clari-
fied. CDCArg increased the expression of PGC1α and
its related gene PPARα. This may accelerate mitochon-
drial oxidation of fat. Previously it has been reported
that bile acids suppress PGC1 activity via the FXR and
SHP pathway [26]. Since CDCArg is a different chemical
structure compared natural bile acids, and was unable to
activate the FXR pathway it does not suppose to suppress
the PGC pathway and may regulate its expression by
cAMP dependent pathway. Surprisingly, CDCArg also
suppressed SREBP-1 expression probably in a mechanism
that may be independent of SHP expression. All of these
effects culminate in improvement of liver steatosis in the
mice model.
In conclusion: conjugate of the bile acid chenodeoxy-
cholic acid and the positively charged amino acid argin-
ine was found to be not toxic in mice. The compound
was evaluated as a liver protective agent in a model of
NAFLD. These results indicate that the compound did
not potentiate cholesterol accumulation in the liver and
protected the liver from damage caused by a HFD rich
in saturated fat. This compound was also effective in im-
proving the metabolic condition of rodents treated with
HFD and was found to be effective as anti-obesity agent
in a mouse model of diet-induced obesity.
Methods
Animals and diets
Five-week-old C57BL/6 J male mice (purchased from Harlan
Laboratories, Israel) were housed in a controlled en-
vironment (22–24°C, 60% humidity and 12 h light-
12 h dark).
Experiments for prevention and treatment of NASH
were performed. All bile acids and analogues were ad-
mixture into the diet. Fat source was palm stearin.
A) Prevention study- mice were randomly divided into
five dietary groups (n = 8-9 each group). (1) Low-fat diet
group (Control, LFD, 16% calories from fat). (2) High-fat
diet group (HFD, 60% calories from fat). (3) HFD + CA
(HFD + CA, 60% calories from fat + 0.5% w/w CA). (4)
High-fat diet + chenodeoxycholyl-arginine ethyl ester
(CDCArg) (HFD + CDCArg, 60% calories from fat +
0.5% w/w CDCArg). (5) High-fat diet + L-Arginine
(HFD + Arg, 60% calories from fat + 1.25% w/v Arginine
in drinking water). All mice had free access to food and
water (ad libitum).
In our experiments we did not used CDCA as control
to CDCArg due to it known hepatotoxicity. Therefore,
CA which is the other primary bile acid was used.
B) Treatment study - mice were randomly divided into
two dietary groups: (1) Low-fat diet group (Control, 16%kilo calories from fat, n = 5); (2) HFD (n = 16). After
10 weeks of dietary treatment, the HFD group was di-
vided randomly into two equal groups (n = 8 in each
group): (a) continued the previous HFD treatment (b)
HFD + 0.5% w/w CDCArg. Food consumption and
weight gain were evaluated and animals were adjusted to
a pair fed diet of 15–16 k-calories/day/mouse.
Rat study
Since cholesterol has been designated recently to pro-
mote fatty liver disease and NASH [27,28], Therefore,
male Sprague Dawley rats (8 per group) 160–200 gram
were supplemented for 6 weeks with control diet (16%
calories from fat), high cholesterol diet (HCD) (1%),
HCD + 0.5% w/w CA, and HCD + 0.5% w/w CDCArg.
Body weight was measured weekly and food intake was
measured daily.
Animal were sacrificed after an overnight fasting
All animal procedures were approved by the local
IACUC. Effect of Arginine-bile acid conjugats and chol-
esterol component of atherogenic diet on liver function
AG-11-13096-2. Genomic and functional study of the
fatty liver syndrome AG-10-12636-3.
Chemical synthesis of CDCArg
A bile acid-arginine amino acid conjugate was prepared
(Figure 1). The synthesized compound CDCArg was
prepared and analytically characterized by Radikal thera-
peutics Inc, Herzelia, Israel (February 19, 2013) using
LC-MS and NMR analysis. Purity of more than 95% was
evaluated by HPLC- diode array detector.
Liver histology
Animals were sacrificed and liver tissues were removed
and fixed in 4% paraformaldehyde at room temperature.
Liver sections were subjected to hematoxylin-eosin stain-
ing (PathoVet Veterinary Pathology Services, Rehovot,
Israel).
Blood parameters
Animal blood was taken from the inferior vena cava after
anesthesia upon sacrificed. Blood glucose levels were mea-
sured using a handheld glucometer (Medisense). Analysis
of plasma SGOT, SGPT, Alkaline Phosphatase, electrolytes
(Na, Cl, K), creatinine and lipid profile (cholesterol and
triglycerides) levels were performed by American Laboratories
Ltd., Herzelia, Israel. Leptin and insulin levels were de-
tected using a luminex assay kit (Millipore, Israel).
Biochemical analysis
Total lipids were extracted from feces using Folch’s
method [29] after collecting feces during weeks: 9–10
and 12–13.
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Glucose tolerance was assessed using the intraperitoneal
glucose tolerance test (IPGTT) in mice during the eighth
and the fourteenth weeks of the study (experiment no.2).
IPGTT was performed in 12 hours-fasted mice by inject-
ing glucose (2 g/kg in 20% solution) intraperitoneally.
Blood samples were obtained by cutting the tail tip and
glucose concentration was measured after 0, 30, 60, 90,
and 120 minutes.
Analysis of gene expression
Genes which modulate by bile acids treatment were
evaluated: Gene expression analyses were performed by
RT and real time PCR using the following primers for
mice and rats. SREBP1c was analyzed by western blot
analysis and loading control was done by beta actin.
Abs: Anti SREBP-1 Santa Cruse (Sc-367); Secondary goat
Anti-Rabbit IgG, Jackson ImmunoResearch, Mouse Anti-
Actin (612656) BD Transduction Laboratories. Secondary
goat Anti-mouse IgG, Jackson ImmunoResearch.
Mouse-
FXR r – 5'-TCA CTG CAC ATC CCA GAT CTC-3'
FXR f – 5'-TCC GGA CAT TCA ACC ATC AC-3'
SHP r – 5'-AGG ATC GTT CCC TTC AGG TA-3'
SHP f – 5'-CAG CGC TGC CTG GAG TCT-3'
18S f – 5'-ACC GCA GCT AGG AAT AAT GG-3'
18S r – 5'-CCT CAG TTC CGA AAA CCA AC-3'
PPAR-alpha f-5'-GTC ACA CAA TGC AAT TCG CTT
T-3
PPAR-alpha r-5'-TTT GCT TTT TCA GAT CTT GGC
A-3'
PGC-1 alpha f- 5'-AAA CCC TGC CAT TGT TAA G-3'
PGC-1 alpha r- 5'-TGA CAA ATG CTC TTC GCT TT-3'
GAPDH f - 5'-GCA TCT TGG GCT ACA CTG AG-3'
GAPDH f - 5'-AGA GTG GGA GTT GCT GTT GA-3'
Rat-
SHP r – 5'-AGC CGT CGC TGA TCC TCA TG-3'
SHP f – 5'-ACT GCC TGT GCC AGC AAC AC-3'
18S f – 5'-CAC GGA CAG GAT TGA CAG AT-3'
18S r – 5'-CAA ATC GCT CCA CCA ACT AA-3'.
Isolation and culturing of rat hepatocytes
Hepatocytes were isolated as follow: Briefly, after anesthesia,
rat livers were perfused with Hanks’ balanced salt solu-
tion (HBSS) containing 1 mM EGTA, followed by perfu-
sion with 0.05% collagenase (cat.LS004177, Worthington,
Lakeswood, NJ) in HBSS in a recirculating matter. The
liver was then detached and filtered through a 70 μm
nylon mesh and cells were sedimented by centrifugation.
Cells were plated onto six-well plates covered with fi-
bronectin (700,000 cells/ml) and grown in low glucose
Dulbecco’smodified Eagle’s medium (DMEM) supplementedwith 10% fetal calf serum, 1% L-glutamine and 100 μg/
ml streptomycin, when kept at 37°C in humidified at-
mosphere (95% air and 5% CO2) [30,31].Statistical analysis
Statistical analysis was performed using one way ANOVA
and post HOC test Fisher's least significant difference test
for experiments with multiple groups. Differences were
considered significant at P < 0.05. The use of other statis-
tical tests is mentioned in the figure legends.Additional files
Additional file 1: Figure S1. Lack of toxic effects of CDCArg as
indicated by electrolyte balance and renal function. Mice were fed
(ad libitum) for 5 weeks with LFD, HFD, HFD+CA, HFD+CDCArg and
HFD+Arg. (A) Serum creatinine levels. (B-D) Serum electrolytes (sodium,
potassium and chloride, respectively) levels.
Additional file 2: Figure S2. Expression of SHP following treatment
with bile acids in isolated rat hepatocytes: Primary rat hepatocytes were
isolated and seeded at concentration of 2 x106 cells per well (in 6 well
plates). Cells were treated with 0.05 mg/ml of cholesterol and with 100
μM of CDCArg or CDCA (n=3, p<0.05) for 18 h.
Additional file 3: Figure S3. Effect of CDCArg on lipogenic gene
expression and energy expenditure related genes in the liver. Treatments:
Mice were fed with LFD for 14 weeks or with HFD for 10 weeks. At week
10 the HFD group was divided randomly into two equal groups that
were pair fed. One group received HFD, while the other group received
HFD+CDCArg. mRNA levels of (A) PGC1α, (B) PPARα. (C) Protein level of
sterol regulatory element binding protein 1c (SREBP1). *p<0.05,
statistically different from control by student t-test. GAPDH was used as
housekeeping normalizing gene.
Additional file 4: Figure S4. Effect of CDCArg and cholic acid (CA) in
dietary cholesterol-induced liver damage. Rats were treated with LFD
(control) or LFD + cholesterol (1% w/w) for 6 weeks in the presence and
absence of bile acids (0.5% w/w). (A) Liver weight of animals after 6
weeks of diet treatments. Levels of two liver enzymes representing liver
damage. (B) ALT (SGPT) and (C) AST (SGOT) levels. Means with different
letters are statistically different, p<0.05.Abbreviations
NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis;
HCC: Hepatocellular carcinoma; FXR: Farnesoid X receptor; SHP: Small
hetrodimer partner; CA: Cholic acid; NTCP: Na+ /taurocholate cotransporter
polypeptide; CYP7A1: 7 alpha-hydroxylase; CDCArg: L-Arginine ethyl ester
and chenodeoxycholic acid conjugate; CDCA: Chenodeoxycholic acid;
UDCA: Urosodeoxycholic acid; LFD: Low fat diet; HFD: High fat diet; TGR5: G
protein-coupled bile acid receptor; SGPT ALT: Serum glutamic-pyruvic
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PGC1α: Proliferator-activated receptor gamma coactivator 1-alpha;
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